- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04471038
Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-176 in Healthy Adults
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78744
- PPD, Phase 1 Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years and ≤60 years
- Body mass index (BMI) of 19-32 kg/m2
- Subjects must have values in normal ranges for basic labs (i.e., CBC, PT/INR, Chem-7, and LFTs), unless deemed not clinically significant by the PI.
- Estimated glomerular filtration rate ≥90 mL/min at screening, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
- Subjects must agree to:
Not take any prescription or over-the-counter (OTC) medications with the exception of acetaminophen, ibuprofen, vitamins, seasonal allergy medications, and/or contraceptive medications, or others unless approved by the study investigator, for a period 7 days prior to study drug administration (i.e., Day 0). Use one of the following in order to avoid pregnancy: Females who are able to become pregnant (i.e., are not postmenopausal, have not undergone surgical sterilization, and are sexually active with men) must agree to use at least 2 effective forms of contraception from the date of the subject's signing of the informed consent form through 60 days after the last dose of study drug. At least one of the methods of contraception should be a barrier method.
Males who have not undergone surgical sterilization and are sexually active with women must agree to use condoms plus have a partner use at least one additional effective form of contraception from the date of the subject's signing of the informed consent form through 60 days after the last dose of study drug.
Neither females or males should donate oocysts or sperm for use in artificial insemination through 60 days after the last dose of study drug.
Exclusion Criteria:
- Any history of allergy, anaphylaxis, or severe reaction to beef products (including milk and gelatin)
- Any history of allergy, anaphylaxis, or severe reaction to IVIg or human blood products
- Any chronic medical problem/condition that require medications needed to maintain the subject's health. Exceptions to this restriction can be allowed for minor health conditions that are treated with Tylenol, over-the-counter non-steroidal anti-inflammatories, vitamins, seasonal allergy medications, or oral/transdermal/IUD contraceptives, etc. The study investigator will make a determination to exclude a subject based upon their medical history and the type and frequency of the drug substance.
- History of cardiovascular disease, cardiomyopathy, heart failure, or unexplained syncope
- Abnormal clinically significant 12-lead electrocardiogram (ECG), per PI discretion
- Subjects who have been laboratory confirmed or clinically diagnosed with influenza within seven days prior to infusion (by subject history) will be deferred from infusion. Any subject with signs and symptoms of an active respiratory infection on the day of infusion will be deferred until the infection is cleared in the opinion of the investigator. Subjects that present with an active upper respiratory infection on the day of infusion will be tested with an FDA licensed Influenza A/B Antigen Test. Signs and symptoms constituting an upper respiratory infection include cough, sore throat, or rhinorrhea with or without fever.
- Enrollment will be delayed for all patients who have other intercurrent infections (e.g., gastroenteritis, abscess, etc.).
- Women who are breast-feeding
- Positive urine or serum pregnancy test
- Positive urine drug screen (UDS)
- Clinically significant results, including laboratory results, as determined by study investigator
- Positive rheumatoid factor
- IgA deficiency (defined as IgA less than 7 mg/dL)
- Participation in another research study with receipt of any investigational drug within 5 half-lives or 30 days, whichever is longer, prior to study drug administration (i.e., Day 0) and until completion of the study
- Participation in any other research study until the completion of the study
- Receipt of blood products within 2 months prior to study drug administration (i.e.Day 0)
- Receipt of any vaccination within 30 days prior to study drug administration (i.e.Day 0)
- Any acute or chronic condition that, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
1 mg/mL SAB-176 in normal (0.9%) Saline; concentration 1 mg/mL (0.1%)
|
Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)
|
Experimental: Cohort 2
10 mg/kgSAB-176 in normal (0.9%) Saline; concentration 4 mg/mL (0.4%)
|
Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)
|
Experimental: Cohort 3
25 mg/kgSAB-176 in normal (0.9%) Saline; concentration 20 mg/mL (2.0%)
|
Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)
|
Experimental: Cohort 4
50 mg/kg SAB-176 in normal (0.9%) Saline; concentration 20 mg/mL (2.0%)
|
Anti-Influenza Human Immunoglobulin Intravenous (Tc bovine derived)
|
Placebo Comparator: Cohort 5
Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
|
Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants having adverse events
Time Frame: 90 days
|
Incidence and severity of other adverse events and severe adverse events (SAE)
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of Serum SAB-176 Titers
Time Frame: 90 Days
|
Measurement of Influenza antibody titers in serum using hemagglutination Inhibition (HAI) assay screening through Study Day 90
|
90 Days
|
Assessment of the PD of SAB-176 administered Intravenously
Time Frame: 90 Days
|
Influenza antibody titers in serum using hemagglutination Inhibition (HAI) assay screening through Study Day 90
|
90 Days
|
Ability of serum SAB-176 levels to neutralize Influenza to day 90
Time Frame: 90 Days
|
Serum levels of SAB-176 using microneutralization (MN) assay through day 90
|
90 Days
|
Immune response elicited by SAB-176
Time Frame: 90 Days
|
Measurement of rheumatoid factor through day 90
|
90 Days
|
Concentration of subject anti-SAB-176 antibodies elicited by SAB-176
Time Frame: 90 Days
|
Measurement of anti-SAB-176 antibodies through day 90
|
90 Days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rebecca N Wood-Horrall, MD, PPD
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SAB-176-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on SAB-176
-
SAb Biotherapeutics, Inc.HvivoActive, not recruiting
-
AbbVieTerminatedAdvanced Solid Tumors CancerUnited States, Australia, Denmark, Spain
-
Arch OncologyCompletedMultiple MyelomaUnited States
-
Centre Hospitalier Régional Metz-ThionvilleCompleted
-
National Institute of Mental Health (NIMH)CompletedPharmacokinetics | AdultUnited States
-
University of AlbertaAlberta Health servicesNot yet recruitingStaph Aureus Bacteremia
-
Arch OncologyMerck Sharp & Dohme LLCCompleted
-
Bridge Biotherapeutics, Inc.TerminatedNSCLCKorea, Republic of
-
Argorna Pharmaceuticals Co., LTDCompleted
-
Val LoweEnrolling by invitationAlzheimer DiseaseUnited States